BioSpace News Archive

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60

Movano Inc . (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, has closed its previously announced initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.00 per share.

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced the closing of its initial public offering (“Offering”) of 5,000,000 ordinary shares at a public offering price of US$5.00 per ordinary share.

ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound , today reported financial results for the three and twelve months ended December 31, 2020 and provided a business update. Highlights of the fourth quarter of 2020 and recent weeks include the following:

Since the start of the coronavirus pandemic more than a year ago, widespread screenings among large numbers of people have been undertaken to limit the spread of the virus.

Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021

Cross-Sectional Study of 589 U.S. Dermatological Clinicians Demonstrating Clinical Utility Was Recently Published in SKIN: The Journal of Cutaneous Medicine

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™)

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules